

Meeting Agenda (draft)

- I **Call to Order. Attendance/Introductions (as applicable)**
- II. **Approval of Minutes – Dec 12, 2018 Meeting**
- III. **Old Business**
- IV. **New Business**
 - A. **New Drug Reviews (22)**
 - 1 Zemdri® (plazomicin) IV
 - 2 Libtayo® (cemiplimab-rwlc) IV
 - 3 Ilumya® (tildrakizumab-asmn) solution for injection
 - 4 Emgality® (galcanezumab gnlm) Sc Inj
 - 5 Lorbreña® (lorlatinib) tabs
 - 6 Epidiolex® cannabidiol) oral solution
 - 7 Talzenna® talazoparib caps
 - 8 Galafold® migalastat) caps
 - 9 Yupelri® revefenacin) inhalation solution-nebulizer
 - 10 Daurismo® glasdegib binimetinib) tabs
 - 11 Xospata® gilteritinib) tabs
 - 12 Mektovi® binimetinib 15mg) tablet
 - 13 Braftovi® (encorafenib, 50mg and 75mg) capsule
 - 14 Xepi® (ozenoxacin 1 %) topical cream
 - 15 Vizimpro® dacomitinib 15mg, 30mg, 45mg) tablet
 - 16 Lumoxiti® (moxetumomab pasudotox-tdfk 1mg) IV inj
 - 17 Tegsedi® (inotersen 284 mg/ 1.5 mL) subQ inj
 - 18 Xofluza® (baloxavir marboxil 20 mg, 40 mg) tablet
 - 19 Onpattro® patisiran 2mg/1mL) IV inj
 - 20 Revcovi® (elapegamase -lvlr 1.6 mg/1 mL) IM
 - 21 Oxervate® (cenegermin-bkbj 0.002 %) ophthalmic Solution
 - 22 Vitrakvi® (larotrectinib 25 mg, 100 mg capsule and 20mg/1mL oral solution)



Pharmacy & Therapeutics Committee
2019 1st Quarter Meeting

Date: Feb 11, 2019
Time: 5pm to 7pm
Location: Aetna Better Health Louisiana Baton Rouge
Facilitators: Vanessa Smith, DPh, Director of Pharmacy

B. Therapeutic Drug Class Reviews (16)

- 1 Movement disorder
- 2 Anthelmintic
- 3 Oral Antifungals
- 4 Ophthalmic antihistamines
- 5 Antihyperlipidemic
- 6 Topical Corticosteroids
- 7 Thyroid Products
- 8 Scabicides
- 9 Progestins
- 10 Antihypertensives
- 11 Antiarrhythmic
- 12 Antidepressants
- 13 Antipsychotics
- 14 Topical Antifungals
- 15 Topical Anesthetics
- 16 Colony Stimulating Factors

C. Policies (Guidelines) Reviews (32)

- 1 Anthelmintics
- 2 Antidepressants Non-Preferred
- 3 Atypical Antipsychotics
- 4 Atypical Antipsychotics Long-Acting Injectable
- 5 Bonjesta Diclegis
- 6 Central Nervous System (CNS) Stimulants
- 7 Corlanor
- 8 Cytokines and Cell Adhesion Molecule (CAM) Antagonists



Pharmacy & Therapeutics Committee
2019 1st Quarter Meeting

Date: Feb 11, 2019
Time: 5pm to 7pm
Location: Aetna Better Health Louisiana Baton Rouge
Facilitators: Vanessa Smith, DPh, Director of Pharmacy

- 9 Direct Renin Inhibitors
- 10 Dupixent
- 11 Egrifta
- 12 Emflaza
- 13 Entresto
- 14 Estradiol Vaginal Cream 0.01%
- 15 Griseofulvin
- 16 Hetlioz
- 17 Intravaginal Progesterone Products
- 18 Juxtapid Kynamro
- 19 Lidocaine Ointment
- 20 Lidocaine Patch ZTlido
- 21 Makena
- 22 Monoamine Depletors Austedo Ingrezza Tetrabenazine
- 23 Multaq
- 24 Non-Stimulant ADHD Medications
- 25 Otezla
- 26 Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9 Inhibitors)
- 27 Praluent Repatha
- 28 Quantity Level Limit
- 29 Tranexamic Acid
- 30 Xifaxan
- 31 Epidiolex
- 32 Korlym

D. New Generic (15)

- 1 EPINEPHRINE INJ 0.3MG EpiPen
- 2 MESALAMINE SUPPOSITORY 1000MG Canasa



Pharmacy & Therapeutics Committee
2019 1st Quarter Meeting

Date: Feb 11, 2019
Time: 5pm to 7pm
Location: Aetna Better Health Louisiana Baton Rouge
Facilitators: Vanessa Smith, DPh, Director of Pharmacy

3	TESTOSTERONE GEL 1.62%	Androgel
4	Glycopyrrolate Tab 1.5 MG	Glycate
5	Clobazam Tab and Suspension	Onfi
6	MINOCYCLINE TAB 55MG ER	Solodyn
7	MICONAZOLE-ZINC-PETROLATUM OINT	Vusion
8	AZELAIC ACID GEL 15%	Finacea Gel
9	LEDIPASVIR-SOFOSBUVIR TAB 90-400MG	Harvoni
10	SOFOSBUVIR/VELPATASVIR TAB 400-100	Epclusa
11	ABIRATERONE TAB 250MG	Zytiga
12	SILODOSIN CAPSULE	Rapaflo
13	AMINOCAPROIC TAB	Amicar
14	PIMECROLIMUS CREAM 1%	Elidel
15	CINACALCET TAB	Sensipar

E. Formulary Updates (see table in packet)

· Negative Impact

F. Common PDL

V. Announcements

Next Meeting April 23, 2019

VI. Adjournment